Company intelligence / Profile preview

Myogen

Westminster, Colorado, USA

Ownership: Private
Employees: ~160
Development stage: Other

Overview

Myogen was a biopharmaceutical company focused on the discovery and development of small molecule drugs for cardiovascular and inflammatory diseases. The company's primary focus was on endothelin receptor antagonists, leading to the development of ambrisentan for pulmonary arterial hypertension. Following successful clinical trials, ambrisentan was eventually approved and marketed as Letairis. Myogen also developed darusentan for resistant hypertension and enoximone for chronic heart failure. In 2006, Gilead Sciences acquired Myogen for $2.5 billion to establish a presence in the cardiovascular market.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

GlaxoSmithKline

Beyond the preview

Go deeper on Myogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myogen.

Explore the full profile